Screener
Fulgent Genetics, Inc. FLGT Compensation and benefits
Discontinued — last reported Q3 '22
Compensation and benefits at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed November 7, 2022.
- Filed
- Nov 7, 2022, 4:36 PM EST
- Fiscal quarter
- Q3 FY2022
- Calendar quarter
- Q3 2022
- Accession
- 0000950170-22-022661
| Line item | Nine Months Ended September 30, 2022 | Nine Months Ended September 30, 2021 |
|---|---|---|
| Cash flow from operating activities: | ||
| Net income from consolidated operations | $165,999 | $402,562 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Equity-based compensation | 22,618 | 10,862 |
| Depreciation and amortization | 22,860 | 7,513 |
| Provision for credit losses | 25,256 | 4,107 |
| Noncash lease expense | 3,311 | 682 |
| Loss on disposal of fixed asset | 300 | 779 |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s compensation and benefits?
- Fulgent Genetics, Inc. (FLGT) reported compensation and benefits of $8.97M in Q3 2022.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about Fulgent Genetics, Inc.'s compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude